TY - JOUR
T1 - Immune checkpoint blockade
T2 - A common denominator approach to cancer therapy
AU - Topalian, Suzanne L.
AU - Drake, Charles G.
AU - Pardoll, Drew M.
N1 - Funding Information:
The authors thank Dr. Julie Brahmer (Johns Hopkins University) for helpful discussions. This work was supported by research funding from Bristol-Myers Squibb (to S.L.T., C.G.D., and D.M.P.), the Melanoma Research Alliance (to S.L.T., C.G.D., and D.M.P.), the National Cancer Institute/NIH (R01 CA142779 [to S.L.T. and D.M.P.] and R01 CA154555 [to C.G.D.]), the Barney Family Foundation (to S.L.T.), the Laverna Hahn Charitable Trust (to S.L.T.), the Commonwealth Foundation (to D.M.P.), and Moving for Melanoma of Delaware (to S.L.T. and D.M.P.). S.L.T. and D.M.P. were also supported by a Stand Up To Cancer—Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. The authors have declared the following financial relationships. S.L.T.: research grants from Bristol-Myers Squibb and consulting for Five Prime Therapeutics, GlaxoSmithKline, and Jounce Therapeutics; C.G.D.: research grants from Bristol-Myers Squibb and Janssen; consulting for Bristol-Myers Squibb, Compugen, Janssen, Novartis, and Roche/Genentech; stock options in Compugen, ImmuneXcite, NexImmune, and Potenza Therapeutics; and patent royalties through his institution, Bristol-Myers Squibb, and Potenza. D.M.P.: research grants from Bristol-Myers Squibb; consulting for Five Prime Therapeutics, GlaxoSmithKline, Jounce Therapeutics, MediImmune, Pfizer, Potenza Therapeutics, and Sanofi; stock options in Jounce and Potenza; and patent royalties through his institution, Bristol-Myers Squibb and Potenza.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/4/13
Y1 - 2015/4/13
N2 - The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
AB - The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.
UR - http://www.scopus.com/inward/record.url?scp=84928062583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928062583&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2015.03.001
DO - 10.1016/j.ccell.2015.03.001
M3 - Review article
C2 - 25858804
AN - SCOPUS:84928062583
SN - 1535-6108
VL - 27
SP - 450
EP - 461
JO - Cancer Cell
JF - Cancer Cell
IS - 4
ER -